<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04174196</url>
  </required_header>
  <id_info>
    <org_study_id>19-284</org_study_id>
    <nct_id>NCT04174196</nct_id>
  </id_info>
  <brief_title>A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma</brief_title>
  <official_title>A Pilot Study Evaluating Lenalidomide and CC-486 in Combination With Radiotherapy For Patients With Plasmacytoma (LENAZART Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if the combination of CC-486 with lenalidomide
      and radiation therapy is a safe and effective treatment for plasmacytoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Anticipated">November 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 19, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure Complete Response</measure>
    <time_frame>At the end of Cycle 6 (each cycle is 28 days)</time_frame>
    <description>Stringent complete response (sCR) will be computed by 2016 IMWG Criteria in addition to identifying no new lesions on PET at the end of 6 cycles of therapy</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Plasmacytoma</condition>
  <condition>Plasmacytoma of Bone</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Participants with Plasmacytoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will have solitary bone plasmacytoma with minimal marrow involvement and participants with relapsed multiple myeloma with plasmacytomas</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-486</intervention_name>
    <description>Participants will be treated with CC-486 and lenalidomide for 6 cycles</description>
    <arm_group_label>Participants with Plasmacytoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Participants will be treated with CC-486 and lenalidomide for 6 cycles</description>
    <arm_group_label>Participants with Plasmacytoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Radiation therapy will be initiated to the plasmacytoma after cycle 2</description>
    <arm_group_label>Participants with Plasmacytoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Cohort 1:

          -  Histologically confirmed solitary plasmacytoma of the bone of lytic bone lesion

          -  Minimal marrow involvement (Detectable clonal bone marrow plasma cells by multicolor
             flow cytometry and &lt;/= 10% clonal plasma cells in a bone marrow biopsy by
             immunohistochemistry, morphology, or flow cytometry)

          -  Secretory M protein &lt; 3 g/dL

        Cohort 2:

          -  Relapsed multiple myeloma with plasmacytomas appropriate for RT on imaging

          -  Relapsed (reappearance of M-spike/serum FLC) or progressive myeloma defined by a 25%
             increase from nadir in M-spike or involved serum FLB on 2 separate measurements; or
             with bone marrow involvement by clonal plasma cells detectable by IHC.

          -  Any prior number of therapies is permitted, including prior radiation therapy

          -  Allogeneic transplant patients are permitted

        All Cohorts:

          -  Age &gt;/= 18 years

          -  Clinically safe to delay radiation for at least 2 months

          -  Surgical resection of plasmacytoma or stabilization surgery is permitted if necessary
             based on physician judgement

          -  ECOG performance status of 0-1

          -  Anticipated lifespan greater than 3 months

          -  Able and willing to give valid written informed consent

          -  Creatinine clearance &gt;/=30ml/min by Cockroft-Gault method. See section below, &quot;Dosing
             Regimen&quot;, regarding lenalidomide dose adjustment for calculated creatinine clearance
             &gt;/= 30ml/min and &lt;60ml/min

          -  Serum bilirubin levels &lt;/= 1.5 times the upper limit of the normal range for the
             laboratory (ULN). Higher levels are acceptable if these can be attributed to active
             hemolysis or ineffective erythropoiesis of Gilbert's syndrome

          -  AST (SGOT) and ALT (SGPT) &lt;/= 2.5 x ULN

          -  Women of childbearing potential should be advised to avoid becoming pregnant and must
             adhere to the scheduled pregnancy testing a required in the Revlimid REMS program.
             They must be agreeable to use acceptable methods of birth control throughout the
             study:

        Recommendation is for 2 effective contraceptive methods during the study. Adequate forms of
        contraception are double-barrier methods (condoms with spermicidal jelly or foam and
        diaphragm with spermicidal jelly or foam), oral, depo provera, or injectable contraceptive,
        intrauterine devices, and tubal ligation.

          -  Agree to abstain from breastfeeding during study participation and for at least 90
             days after the last dose of investigational product (IP). Men should be advised to not
             father a child while receiving treatment with azacitidine. Male patients with female
             partners who are of childbearing potential: Recommendation is for the patient and
             partner use at least 2 effective contraceptive methods, as described above, during the
             study and for 3 months following the last dose of study drug.

        Refrain from semen or sperm donation while taking IP and for at least 90 days after the
        last dose of IP.

          -  Willing to be registered into the mandatory Revlimid REMS program, and be willing and
             able to comply with the requirements of the REMS program.

          -  Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients
             intolerant to ASA may use physician's choice of anticoagulation).

          -  Able to swallow oral medication

          -  Hematologic criteria: Hemoglobin &gt;/= 9 g/dL, platelets &gt;/= 50,000 and ANC &gt;/= 1

        Exclusion Criteria:

        Subjects should not enter the study if any of the following exclusion criteria are
        fulfilled:

          -  Pregnant or breast feeding females. (Lactating females must agree not to breast feed
             while taking azacitidine).

          -  Uncontrolled systemic fungal, bacterial or viral infection (defined as ongoing
             signs/symptoms related the infection without improvement despite appropriate
             antibiotics, antiviral therapy and/or other treatment)

          -  History of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis),
             celiac disease (ie, sprue), prior gastrectomy or upper bowel removal, or any other
             gastrointestinal disorder or defect that would interfere with the absorption,
             distribution, metabolism or excretion of the study drug and/or predispose the subject
             to an increased risk of gastrointestinal toxicity

          -  Abnormal coagulation parameters (PT &gt; 15 seconds, PTT?40 seconds, and/or INR &gt; 1,5)

          -  Significant active cardiac disease within the previous 6 months including:

        NYHA class 4 CHF Unstable angina Myocardial infarction

          -  known or suspected hypersensitivity to azacitidine or mannitol

          -  Known hypersensitivity to thalidomide or lenalidomide

          -  The development of erythema nodosum if characterized by a desquamating rash while
             taking thalidomide or similar drugs

          -  Active viral infection with human immunodeficiency virus (HIV), hepatitis B virus
             (HBV), or hepatitis C virus (HCV) as determined by a positive Polymerase Chain
             Reaction (PCR) will be excluded. Patients who are seropositive because of HBV vaccine
             are eligible. Seropositive status-antibody positive patients with negative PCR on two
             occasions will be eligible

          -  Concurrent systemic chemotherapy with drugs other than CC-486 and lenalidomide.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urvi Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Urvi Shah, MD</last_name>
    <phone>212-639-7016</phone>
    <email>shahu@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander Lesokhin, MD</last_name>
    <phone>212-639-3069</phone>
    <email>lesokhia@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urvi Shah, MD</last_name>
      <phone>212-639-7016</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urvi Shah, MD</last_name>
      <phone>212-639-7016</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urvi Shah, MD</last_name>
      <phone>212-639-7016</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urvi Shah, MD</last_name>
      <phone>212-639-7016</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urvi Shah, MD</last_name>
      <phone>212-639-7016</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urvi Shah, MD</last_name>
      <phone>212-639-7016</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urvi Shah, MD</last_name>
      <phone>212-639-7016</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CC-486</keyword>
  <keyword>Plasmacytoma</keyword>
  <keyword>lenalidomide</keyword>
  <keyword>Plasmacytoma of Bone</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <keyword>19-284</keyword>
  <keyword>multiple myeloma with plasmacytomas</keyword>
  <keyword>multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

